Antares Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Loading...
Loading...
EWING, N.J.--(BUSINESS WIRE)--

Antares Pharma, Inc. ATRS today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:00 a.m. Pacific Time.

A live webcast of the presentation will be available via the “Investor Information/Webcasts” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX® disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX® epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda.

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...